Lung Cancer

Strategy also results in low rates of severe toxic effects

Technique reduces risk of severe lung toxicity and radiation to the heart compared with 3D-CRT

Confirmed responses reached 29.8% in heavily pretreated patients

Randomized data suggest surgery increases risk of death by 28% over first 42 months

Osimertinib plus chemotherapy improved PFS by nearly 9 months versus targeted agent alone

Median overall survival reached 19.3 months in Chinese trial

"How are we here in 2023 having some of these discussions?" bemoans gynecologic cancer expert

Disease progression slowed and need for brain radiation delayed in most patients

Studies show their potential, but reveal clear issues with treatment information reliability

More than half of patients with NSCLC, more than a third of those with CRC responded to divarasib

Experts will discuss the chemotherapy drug shortages and the impact on patients

Path to eliminating these tests, while crucial, will be challenging, researchers say

These tests could soon become a valuable addition to current cancer screening tools

Approach is "potentially practice-changing," editorialist says